Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 11/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9277352 | 0.82 | IDO1 (0.50) | UHRF1IDO1USP30DYRK1ATLR7 | |
| SCHEMBL24060036 | 0.79 | IDO1 (0.41) | UHRF1IDO1USP30DYRK1ATLR7 | |
| SCHEMBL12093732 | 0.78 | IDO1 (0.45) | UHRF1IDO1USP30DYRK1ATLR7 | |
| SCHEMBL13983615 | 0.78 | UHRF1 (0.45) | UHRF1IDO1USP30DYRK1APROKR1 | |
| SCHEMBL12093743 | 0.78 | IDO1 (0.45) | UHRF1IDO1USP30DYRK1ATLR7 | |
| SCHEMBL27306427 | 0.78 | UHRF1 (0.45) | UHRF1IDO1USP30DYRK1APROKR1 | |
| SCHEMBL22601550 | 0.78 | PDE2A (0.43) | UHRF1IDO1USP30TLR7TLR8 | |
| SCHEMBL21583830 | 0.78 | IDO1 (0.38) | UHRF1IDO1USP30DYRK1ATLR7 | |
| SCHEMBL22402327 | 0.77 | IDO1 (0.44) | UHRF1IDO1USP30DYRK1ATLR7 | |
| SCHEMBL20031175 | 0.77 | UHRF1 (0.43) | UHRF1IDO1USP30DYRK1ATLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | BRCA1, VHL, TFEB | UHRF1 1223/4885IDO1 4826/4885USP30 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.